Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
November 2024
Efficacy and safety of sodium-glucose co-transporter 2 inhibitors for the primary prevention of cardiovascular, renal events and safety outcomes in patients with systemic lupus erythematosus and comorbid type 2 diabetes: A population-based target trial emulation
Arthritis Rheumatol 2024. Epub ahead of print DOI: 10.1002/art.43037
Ma et al. assessed the efficacy and safety of sodium-glucose co-transporter 2 inhibitors (SGLT2i) compared with dipeptidyl peptidase 4 inhibitors (DPP4i) in preventing cardiovascular and renal events in patients with both SLE and type 2 diabetes (T2D). SGLT2i use significantly reduced risks for acute kidney injury, chronic kidney disease, end-stage renal disease, and heart failure, though it increased genital infection risk.
Keywords:
October 2024
ANA-associated arthritis: clinical and biomarker characterization of a population for basket trials
Rheumatol 2024 2024;00:1–11 DOI 10.1093/rheumatology/keae269
Arnold et al. assessed musculoskeletal (MSK) inflammation in ANA-associated rheumatic diseases (RMDs) and redefined ANA-associated arthritis into two distinct multi-disease clusters based on disease activity, which may support a more targeted approach to treatment. The authors confirmed that MSK inflammation is a key feature across diagnoses and responded similarly to treatments.
Keywords:
July 2024
Efficacy and safety of upadacitinib or elsubrutinib alone or in combination for systemic lupus erythematosus: A Phase 2 randomized controlled trial
Arthritis Rheumatol 2024 DOI: 10.1002/art.42926 Epub ahead of print
Daily oral upadacitinib 30 mg and ABBV-599 high dose (elsubrutinib 60 mg QD + upadacitinib 30 mg) were effective in multiple outcome measures including disease activity, flares, time to first flare, and joint counts.
Keywords:
February 2024
Development of the American College of Rheumatology's Patient-reported Outcome Quality Measures for Systemic Lupus Erythematosus
Arthritis Care Res (Hoboken). 2024 doi: 10.1002/acr.25301. Epub ahead of print.
Expert workgroup members and patient partners recommend that clinicians assess depression and physical function at least once yearly in all people with SLE. Additional patient reported outcome measures addressing cognition and fatigue can also be assessed.